Fool - Investing News
15 Jul 2026, 05:00 UTC · 2h ago
2 Beaten-Down GLP-1 Stocks to Buy on the Dip
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Fool - Investing News
15 Jul 2026, 05:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Novo Nordisk's oral Wegovy has exceeded three million prescriptions in the U.S. and recently received approval in the European Union. — Successful expansion into oral delivery and new geographic markets directly drives revenue growth and broadens the patient base.
+0.60Novo Nordisk is developing triple agonist medicines, including UBT251, which has shown strong results in phase 2 studies. — Triple agonists could offer superior efficacy over current dual agonists (like Zepbound), potentially shifting market share back to Novo.
+0.40Kailera Therapeutics currently has no products on the market, making it a high-risk investment susceptible to clinical or regulatory setbacks. — The lack of commercialized products creates a high-risk profile and binary outcome dependency for investors.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Despite recent setbacks, the company has a smashing success with oral Wegovy and a promising triple agonist pipeline.
Mentioned as providing stiff competition and possessing the best-selling anti-obesity therapy on the market.
Described as a risky stock with no products on the market and a declining share price since going public.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
